Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from Venus Medtech (Hangzhou), Inc. Class H ( (HK:2500) ).
Venus Medtech (Hangzhou) Inc. has disclosed the current composition of its board of directors, detailing the mix of executive, non-executive, and independent non-executive directors and their respective responsibilities. The announcement clarifies the leadership structure across key governance committees, with independent directors chairing the audit, remuneration and assessment, and nomination committees, underscoring the company’s emphasis on oversight and corporate governance.
Chairman and independent non-executive director Ting Yuk Anthony Wu serves as a member or chair of several committees, while fellow independent directors Chi Wai Suen and John Junhua Gu hold chair and member roles across the audit, remuneration, and nomination bodies. This structure signals a strong role for independent oversight in the company’s governance framework, which may reassure investors and other stakeholders about checks and balances at the board level.
More about Venus Medtech (Hangzhou), Inc. Class H
Venus Medtech (Hangzhou) Inc. is a medical technology company based in the People’s Republic of China and listed in Hong Kong under stock code 2500. The company operates in the healthcare sector, focusing on innovative medical devices, and is governed by a board comprising executive, non-executive, and independent non-executive directors to oversee strategy and governance.
Average Trading Volume: 1,173,553
Technical Sentiment Signal: Sell
Current Market Cap: HK$701.2M
See more data about 2500 stock on TipRanks’ Stock Analysis page.